Publications by authors named "Seth A Wander"

24Publications

Acquired FGFR and FGF Alterations Confer Resistance to Estrogen Receptor (ER) Targeted Therapy in ER Metastatic Breast Cancer.

Authors:
Pingping Mao Ofir Cohen Kailey J Kowalski Justin G Kusiel Jorge E Buendia-Buendia Michael S Cuoco Pedro Exman Seth A Wander Adrienne G Waks Utthara Nayar Jon Chung Samuel Freeman Orit Rozenblatt-Rosen Vincent A Miller Federica Piccioni David E Root Aviv Regev Eric P Winer Nancy U Lin Nikhil Wagle

Clin Cancer Res 2020 Nov 28;26(22):5974-5989. Epub 2020 Jul 28.

Center for Cancer Precision Medicine, Dana-Farber Cancer Institute, Boston, Massachusetts.

View Article and Find Full Text PDF
November 2020

The Genomic Landscape of Intrinsic and Acquired Resistance to Cyclin-Dependent Kinase 4/6 Inhibitors in Patients with Hormone Receptor-Positive Metastatic Breast Cancer.

Authors:
Seth A Wander Ofir Cohen Xueqian Gong Gabriela N Johnson Jorge E Buendia-Buendia Maxwell R Lloyd Dewey Kim Flora Luo Pingping Mao Karla Helvie Kailey J Kowalski Utthara Nayar Adrienne G Waks Stephen H Parsons Ricardo Martinez Lacey M Litchfield Xiang S Ye Chunping Yu Valerie M Jansen John R Stille Patricia S Smith Gerard J Oakley Quincy S Chu Gerald Batist Melissa E Hughes Jill D Kremer Levi A Garraway Eric P Winer Sara M Tolaney Nancy U Lin Sean G Buchanan Nikhil Wagle

Cancer Discov 2020 Aug 13;10(8):1174-1193. Epub 2020 May 13.

Center for Cancer Precision Medicine, Dana-Farber Cancer Institute, Boston, Massachusetts.

View Article and Find Full Text PDF
August 2020

Cyclin-dependent kinase 4 and 6 inhibitors for hormone receptor-positive breast cancer: past, present, and future.

Authors:
Laura M Spring Seth A Wander Fabrice Andre Beverly Moy Nicholas C Turner Aditya Bardia

Lancet 2020 03;395(10226):817-827

Department of Medical Oncology, Massachusetts General Hospital Cancer Center, Harvard Medical School, Boston, MA, USA. Electronic address:

View Article and Find Full Text PDF
March 2020

Amplification Mediates Endocrine Resistance but Retains TORC Sensitivity in Metastatic Hormone Receptor-Positive (HR) Breast Cancer.

Authors:
Joshua Z Drago Luigi Formisano Dejan Juric Andrzej Niemierko Alberto Servetto Seth A Wander Laura M Spring Neelima Vidula Jerry Younger Jeffrey Peppercorn Megan Yuen Giuliana Malvarosa Dennis Sgroi Steven J Isakoff Beverly Moy Leif W Ellisen A John Iafrate Carlos L Arteaga Aditya Bardia

Clin Cancer Res 2019 11 1;25(21):6443-6451. Epub 2019 Aug 1.

Department of Medicine, Massachusetts General Hospital Cancer Center and Harvard Medical School, Boston, Massachusetts.

View Article and Find Full Text PDF
November 2019

Genetics to epigenetics: targeting histone deacetylases in hormone receptor-positive metastatic breast cancer.

Authors:
Seth A Wander Laura M Spring Aditya Bardia

Lancet Oncol 2019 06 27;20(6):746-748. Epub 2019 Apr 27.

Massachusetts General Hospital Cancer Center, Harvard Medical School, Boston, MA, USA. Electronic address:

View Article and Find Full Text PDF
June 2019

p27 transcriptionally coregulates cJun to drive programs of tumor progression.

Authors:
Hyunho Yoon Minsoon Kim Kibeom Jang Miyoung Shin Alexandra Besser Xue Xiao Dekuang Zhao Seth A Wander Karoline Briegel Lluis Morey Andy Minn Joyce M Slingerland

Proc Natl Acad Sci U S A 2019 04 15;116(14):7005-7014. Epub 2019 Mar 15.

Braman Family Breast Cancer Institute, Sylvester Comprehensive Cancer Center, University of Miami Miller School of Medicine, Miami, FL 33136;

View Article and Find Full Text PDF
April 2019

MicroRNA-Mediated Suppression of the TGF-β Pathway Confers Transmissible and Reversible CDK4/6 Inhibitor Resistance.

Authors:
Liam Cornell Seth A Wander Tanvi Visal Nikhil Wagle Geoffrey I Shapiro

Cell Rep 2019 03;26(10):2667-2680.e7

Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA 02215, USA; Department of Medicine, Brigham and Women's Hospital and Harvard Medical School, Boston, MA 02115, USA. Electronic address:

View Article and Find Full Text PDF
March 2019

CDK 4/6 Inhibitors in Breast Cancer: Current Controversies and Future Directions.

Authors:
Laura M Spring Seth A Wander Mark Zangardi Aditya Bardia

Curr Oncol Rep 2019 02 26;21(3):25. Epub 2019 Feb 26.

Massachusetts General Hospital Cancer Center, Harvard Medical School, Lawrence House 304, 10 North Grove St, Boston, MA, 02114, USA.

View Article and Find Full Text PDF
February 2019

Acquired HER2 mutations in ER metastatic breast cancer confer resistance to estrogen receptor-directed therapies.

Authors:
Utthara Nayar Ofir Cohen Christian Kapstad Michael S Cuoco Adrienne G Waks Seth A Wander Corrie Painter Samuel Freeman Nicole S Persky Lori Marini Karla Helvie Nelly Oliver Orit Rozenblatt-Rosen Cynthia X Ma Aviv Regev Eric P Winer Nancy U Lin Nikhil Wagle

Nat Genet 2019 02 10;51(2):207-216. Epub 2018 Dec 10.

Center for Cancer Precision Medicine, Dana-Farber Cancer Institute, Boston, MA, USA.

View Article and Find Full Text PDF
February 2019

Isocitrate dehydrogenase 1 and 2 mutations, 2-hydroxyglutarate levels, and response to standard chemotherapy for patients with newly diagnosed acute myeloid leukemia.

Authors:
Andrew M Brunner Donna S Neuberg Seth A Wander Hossein Sadrzadeh Karen K Ballen Philip C Amrein Eyal Attar Gabriela S Hobbs Yi-Bin Chen Ashley Perry Christine Connolly Christelle Joseph Meghan Burke Aura Ramos Ilene Galinsky Katharine Yen Hua Yang Kimberly Straley Sam Agresta Sophia Adamia Darrell R Borger Anthony Iafrate Timothy A Graubert Richard M Stone Amir T Fathi

Cancer 2019 02 13;125(4):541-549. Epub 2018 Nov 13.

Massachusetts General Hospital, Boston, Massachusetts.

View Article and Find Full Text PDF
February 2019

Blocking the Cycle: Cyclin-Dependent Kinase 4/6 Inhibitors in Metastatic, Hormone Receptor-Positive Breast Cancer.

Authors:
Seth A Wander Erica L Mayer Harold J Burstein

J Clin Oncol 2017 Sep 3;35(25):2866-2870. Epub 2017 Jun 3.

Seth A. Wander, Erica L. Mayer, and Harold J. Burstein, Dana-Farber Cancer Institute; Brigham & Women's Hospital; Harvard Medical School, Boston, MA.

View Article and Find Full Text PDF
September 2017

Phase I study of the aurora A kinase inhibitor alisertib with induction chemotherapy in patients with acute myeloid leukemia.

Authors:
Amir T Fathi Seth A Wander Traci M Blonquist Andrew M Brunner Philip C Amrein Jeffrey Supko Nicole M Hermance Amity L Manning Hossein Sadrzadeh Karen K Ballen Eyal C Attar Timothy A Graubert Gabriela Hobbs Christelle Joseph Ashley M Perry Meghan Burke Regina Silver Julia Foster Meghan Bergeron Aura Y Ramos Tina T Som Kaitlyn M Fishman Kristin L McGregor Christine Connolly Donna S Neuberg Yi-Bin Chen

Haematologica 2017 04 29;102(4):719-727. Epub 2016 Dec 29.

Massachusetts General Hospital Cancer Center, Harvard Medical School, Boston, USA.

View Article and Find Full Text PDF
April 2017

Erratum to: PI3K/mTOR inhibition can impair tumor invasion and metastasis in vivo despite a lack of antiproliferative action in vitro: implications for targeted therapy.

Authors:
Seth A Wander Dekuang Zhao Alexandra H Besser Feng Hong Jianqin Wei Tan A Ince Clara Milikowski Nanette H Bishopric Andy J Minn Chad J Creighton Joyce M Slingerland

Breast Cancer Res Treat 2016 Apr;156(2):405-6

Braman Family Breast Cancer Institute at Sylvester, Miller School of Medicine, University of Miami, Miami, FL, 33136, USA.

View Article and Find Full Text PDF
April 2016

Elevation of Urinary 2-Hydroxyglutarate in IDH-Mutant Glioma.

Authors:
Amir T Fathi Brian V Nahed Seth A Wander A John Iafrate Darrell R Borger Ranliang Hu Ashraf Thabet Daniel P Cahill Ashley M Perry Christelle P Joseph Alona Muzikansky Andrew S Chi

Oncologist 2016 Feb 1;21(2):214-9. Epub 2016 Feb 1.

Division of Neuro-Oncology, Department of Neurology, Massachusetts General Hospital and Harvard Medical School, Boston, Massachusetts, USA Division of Hematology/Oncology, Department of Neurology, Massachusetts General Hospital and Harvard Medical School, Boston, Massachusetts, USA.

View Article and Find Full Text PDF
February 2016

Interactions between Adipocytes and Breast Cancer Cells Stimulate Cytokine Production and Drive Src/Sox2/miR-302b-Mediated Malignant Progression.

Authors:
Manuel Picon-Ruiz Chendong Pan Katherine Drews-Elger Kibeom Jang Alexandra H Besser Dekuang Zhao Cynthia Morata-Tarifa Minsoon Kim Tan A Ince Diana J Azzam Seth A Wander Bin Wang Burcu Ergonul Ram H Datar Richard J Cote Guy A Howard Dorraya El-Ashry Pablo Torné-Poyatos Juan A Marchal Joyce M Slingerland

Cancer Res 2016 Jan 7;76(2):491-504. Epub 2016 Jan 7.

Braman Family Breast Cancer Institute, UM Sylvester Comprehensive Cancer Center, University of Miami Miller School of Medicine, Miami, Florida. Department of Biochemistry and Molecular Biology, University of Miami Miller School of Medicine, Miami, Florida. Donald and Sheila Fuente Graduate Program in Cancer Biology, University of Miami Miller School of Medicine, Miami, Florida. Department of Medicine, University of Miami Miller School of Medicine, Miami, Florida.

View Article and Find Full Text PDF
January 2016

Biochemical, Epigenetic, and Metabolic Approaches to Target IDH Mutations in Acute Myeloid Leukemia.

Authors:
Amir T Fathi Seth A Wander Rawan Faramand Ashkan Emadi

Semin Hematol 2015 Jul 17;52(3):165-71. Epub 2015 Mar 17.

University of Maryland, School of Medicine, Marlene and Stewart Greenebaum Cancer Center, Baltimore, MD. Electronic address:

View Article and Find Full Text PDF
July 2015

The evolving role of FLT3 inhibitors in acute myeloid leukemia: quizartinib and beyond.

Authors:
Seth A Wander Mark J Levis Amir T Fathi

Ther Adv Hematol 2014 Jun;5(3):65-77

Massachusetts General Hospital, Harvard Medical School, Zero Emerson Place, Suite 118, Boston, MA 02114, USA.

View Article and Find Full Text PDF
June 2014

Triple negative breast cancer initiating cell subsets differ in functional and molecular characteristics and in γ-secretase inhibitor drug responses.

Authors:
Diana J Azzam Dekuang Zhao Jun Sun Andy J Minn Prathibha Ranganathan Katherine Drews-Elger Xiaoqing Han Manuel Picon-Ruiz Candace A Gilbert Seth A Wander Anthony J Capobianco Dorraya El-Ashry Joyce M Slingerland

EMBO Mol Med 2013 10 27;5(10):1502-22. Epub 2013 Aug 27.

Braman Family Breast Cancer Institute, Sylvester Comprehensive Cancer Center, University of Miami Miller School of Medicine, Miami, FL, USA; Department of Biochemistry and Molecular Biology, University of Miami Miller School of Medicine, Miami, FL, USA.

View Article and Find Full Text PDF
October 2013

PI3K/mTOR inhibition can impair tumor invasion and metastasis in vivo despite a lack of antiproliferative action in vitro: implications for targeted therapy.

Authors:
Seth A Wander Dekuang Zhao Alexandra H Besser Feng Hong Jianqin Wei Tan A Ince Clara Milikowski Nanette H Bishopric Andy J Minn Chad J Creighton Joyce M Slingerland

Breast Cancer Res Treat 2013 Apr 21;138(2):369-81. Epub 2013 Feb 21.

Braman Family Breast Cancer Institute at Sylvester, Miller School of Medicine, University of Miami, Miami, FL 33136, USA.

View Article and Find Full Text PDF
April 2013

Next-generation mTOR inhibitors in clinical oncology: how pathway complexity informs therapeutic strategy.

Authors:
Seth A Wander Bryan T Hennessy Joyce M Slingerland

J Clin Invest 2011 Apr 1;121(4):1231-41. Epub 2011 Apr 1.

Braman Family Breast Cancer Institute, Sylvester Comprehensive Cancer Center, University of Miami Miller School of Medicine, Miami, Florida 33136, USA.

View Article and Find Full Text PDF
April 2011

p27: a barometer of signaling deregulation and potential predictor of response to targeted therapies.

Authors:
Seth A Wander Dekuang Zhao Joyce M Slingerland

Clin Cancer Res 2011 Jan 21;17(1):12-8. Epub 2010 Oct 21.

Braman Family Breast Cancer Institute, University of Miami Sylvester Comprehensive Cancer Center, Department of Medicine, University of Miami Miller School of Medicine, Miami, Florida 33136, USA.

View Article and Find Full Text PDF
January 2011

Combined Src and ER blockade impairs human breast cancer proliferation in vitro and in vivo.

Authors:
Yi Chen Edwin A Alvarez Diana Azzam Seth A Wander Natalia Guggisberg Mercè Jordà Zhenlin Ju Bryan T Hennessy Joyce M Slingerland

Breast Cancer Res Treat 2011 Jul 29;128(1):69-78. Epub 2010 Jul 29.

Braman Family Breast Cancer Institute, University of Miami Sylvester Comprehensive Cancer Center, Miami, FL, 33136, USA.

View Article and Find Full Text PDF
July 2011

p27 as Jekyll and Hyde: regulation of cell cycle and cell motility.

Authors:
Michelle D Larrea Seth A Wander Joyce M Slingerland

Cell Cycle 2009 Nov 11;8(21):3455-61. Epub 2009 Nov 11.

Braman Family Breast Cancer Institute, University of Miami Sylvester Comprehensive Cancer Center and Department of Biochemistry and Molecular Biology, UM Miller School of Medicine, Miami, FL, USA.

View Article and Find Full Text PDF
November 2009

RSK1 drives p27Kip1 phosphorylation at T198 to promote RhoA inhibition and increase cell motility.

Authors:
Michelle D Larrea Feng Hong Seth A Wander Thiago G da Silva David Helfman Deborah Lannigan Jeffrey A Smith Joyce M Slingerland

Proc Natl Acad Sci U S A 2009 Jun 22;106(23):9268-73. Epub 2009 May 22.

Department of Biochemistry and Molecular Biology, Braman Family Breast Cancer Institute, University of Miami Sylvester Comprehensive Cancer Center, Miami, FL 33136, USA.

View Article and Find Full Text PDF
June 2009